Sahajanand Medical Technologies Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹24(6.98%)
Premium (ELP)
Market participation is actively sought for Sahajanand Medical Technologies Limited's's ongoing Initial Public Offering, which encompasses a total value of 1,38,22,116 Shares. The offering includes TBD in fresh equity and ₹475.48 Cr in existing share sales through the OFS mechanism.
The currently applicable price range of ₹327 to ₹344 and minimum investment of 43 shares define participation criteria. The active subscription period represents a limited opportunity for investor engagement.
The application window will close on Oct 19, 2026, followed by allotment processing on Oct 21, 2026. Successful applicants will see their holdings listed for trading on Oct 23, 2026 at the NSE, BSE platform.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Founded in 2001 by Mr. Dhirajlal Kotadia, Sahajanand Medical Technologies Ltd. is a medical device company that focuses on advanced Class III and Class C/D devices used mainly in vascular and structural heart treatments. The company was the first in the world to receive CE certification for a drug-eluting stent with a biodegradable polymer called Infinnium. Its product range includes coronary stents and balloons for vascular interventions, technologies like TAVI and occluders for structural heart treatments, as well as renal stents and drug-coated balloons. The company operates R&D centres in India and Thailand and has a strong innovation base with over 100 granted patents and several pending applications. Its key products, including Supraflex Cruz, Hydra, and Cocoon, are supported by multiple clinical studies and are used in more than 76 countries. Sahajanand follows a global distribution strategy combining direct sales, hybrid models, and distributor partnerships across different markets. As of March 31, 2025, the company had over 1,400 employees along with consultants and contract staff supporting its operations.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
The expected premium (GMP) is based on market buzz and unofficial trading. It should not be considered as the guaranteed listing price. Always refer to the RHP and seek advice from a financial expert before making investment decisions.
💡 Read our detailed guide: What is IPO Grey Market Premium (GMP) & How It Works?•📈 Track all live rates on IPO GMP Today
- Advanced & Technologically Sophisticated Products: The Company is among a select group of global Class III (and Class C/D) players offering advanced cardiovascular implants, including DES, PTCA balloons, TAVI systems and Occluders. Its products are supported by clinical evidence and comply with stringent domestic and international regulatory standards.
- Strong Research & Development Capabilities: The Company operates two R&D facilities in India and Thailand, supported by 156 professionals. It holds over 119 patents granted globally, with 78 applications pending, supporting ongoing innovation in products such as its proprietary LDZ link and patented AVDC system.
- Strong Market Position in India & Overseas: The Company held nearly 25% market share by DES sales volume in India in FY2026. It also ranked among the top five companies by DES sales volume in Germany, Spain, Poland and Brazil, and by Occluder sales volume in Thailand, South Korea and India.
- Strict Regulatory Compliance Requirements: The Company operates under stringent regulations across multiple markets, including India’s Drugs and Cosmetics Act and the EU Medical Device Regulation. Delays in approvals, adverse regulatory actions or failure to maintain required certifications could restrict product sales and negatively affect business prospects.
- Manufacturing & Operational Risks: The Company’s three manufacturing facilities may face quality control issues, operational disruptions, outdated machinery or underutilised capacity. These challenges could increase production costs, interrupt operations and adversely affect product quality, sales and reputation.
- Dependence on Key Raw Material Suppliers: The top 10 suppliers accounted for 63.61%, 59.15%, 64.37% and 58.88% of total purchases in the three months ended June 30, 2026 and FY2026, FY2025 and FY2024, respectively. Reliance on a limited number of suppliers, or a single supplier for certain critical materials, exposes the Company to supply disruptions and price fluctuations.
- Bhargav Dhirajlal Kotadia
- Dhirajlal Vallabhbhai Kotadia
- Priyanka Dhirajlal Cohen
- Shree Hari Trust
Sahajanand Medical Technologies Limited
Link Intime India Private Limited